The group’s principle activity is to provide monoclonal antibody products. The group’s products include NeoClone(R) and NeoAb(R). The group provides services include project fast tracking, antigen development, tolerization, antibody purification, cell line storage, mAb characterization and additional ascites development. The group operates from United States.
